At certain point of cancer progression, primary localized tumors may disseminate to distant organs, including lymph nodes, lungs, bones, liver, or brain. The current options to treat cancer metastases are highly limited, and frequently not very effective. That is the main reason why metastatic disease is responsible for 90% of cancer patients' deaths. Mechanistically, the development of distant tumor metastasis is a highly complex, multi-step process that requires cooperation between cancer and host cells. While substantial progress has been made in recent years in the biology of tumor metastasis, the precise mechanisms that contribute to the early dissemination, dormancy, and eventual tumor cell colonization, are still not well understood.
The main objective of this Research Topic is to evaluate the molecular, cellular, and organ-level mechanisms of tumor dissemination and the development of novel therapies for the treatment of metastatic disease. We welcome researchers to submit Reviews, Opinions, or Original Research articles focused on the biology and therapy of metastatic disease. We are particularly interested in both pre-clinical and clinical studies with novel findings that will highlight the various aspects of the biology of cancer metastasis and anti-metastatic therapy, including:
- Mechanisms of intravasation and extravasation of cancer cells
- Remodeling of extracellular matrix in the metastatic niche
- Formation of microscopic and macroscopic metastatic colonies
- Tumor cell dormancy
- Roles of macrophages, MDSCs, and bone marrow-derived progenitors in metastasis formation
- Immune infiltration in metastatic tissues
- Anti-metastatic immunotherapy, including antibody-mediated, ADC, and CAR-T cell-targeted therapy for metastasis treatment
- Radiotherapy and chemotherapy for metastatic disease
- Mechanisms of resistance to anti-metastatic therapy.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
At certain point of cancer progression, primary localized tumors may disseminate to distant organs, including lymph nodes, lungs, bones, liver, or brain. The current options to treat cancer metastases are highly limited, and frequently not very effective. That is the main reason why metastatic disease is responsible for 90% of cancer patients' deaths. Mechanistically, the development of distant tumor metastasis is a highly complex, multi-step process that requires cooperation between cancer and host cells. While substantial progress has been made in recent years in the biology of tumor metastasis, the precise mechanisms that contribute to the early dissemination, dormancy, and eventual tumor cell colonization, are still not well understood.
The main objective of this Research Topic is to evaluate the molecular, cellular, and organ-level mechanisms of tumor dissemination and the development of novel therapies for the treatment of metastatic disease. We welcome researchers to submit Reviews, Opinions, or Original Research articles focused on the biology and therapy of metastatic disease. We are particularly interested in both pre-clinical and clinical studies with novel findings that will highlight the various aspects of the biology of cancer metastasis and anti-metastatic therapy, including:
- Mechanisms of intravasation and extravasation of cancer cells
- Remodeling of extracellular matrix in the metastatic niche
- Formation of microscopic and macroscopic metastatic colonies
- Tumor cell dormancy
- Roles of macrophages, MDSCs, and bone marrow-derived progenitors in metastasis formation
- Immune infiltration in metastatic tissues
- Anti-metastatic immunotherapy, including antibody-mediated, ADC, and CAR-T cell-targeted therapy for metastasis treatment
- Radiotherapy and chemotherapy for metastatic disease
- Mechanisms of resistance to anti-metastatic therapy.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.